Skip to content

Vektor vMap™ Clinical Validation Study

Clinical Validation of the Vektor Computational ECG Mapping System (vMap™) for Atrial and Ventricular Arrhythmias/Pacing

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04559061
Enrollment
225
Registered
2020-09-22
Start date
2020-12-01
Completion date
2021-04-06
Last updated
2021-04-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac Arrhythmia, Atrial Fibrillation, Ventricular Arrythmia, Premature Ventricular Complexes Multiple, Ventricular Tachycardia, Ventricular Fibrillation, Premature Atrial Complex, Atrioventricular Reentrant Tachycardia

Brief summary

This is a retrospective, multi center clinical study collecting existing, de-identified subject data from medical records to be analyzed using an independent core laboratory to validate performance of a computational ECG mapping system (vMap™).

Interventions

Retrospective data will be collected from cases where successful ablation was completed.

Sponsors

Experien Group
CollaboratorUNKNOWN
Vektor Medical
Lead SponsorINDUSTRY

Study design

Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
22 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

1. Patient has one of the following clinical arrhythmia/pacing types: * Atrial pacing * Atrial fibrillation * Ventricular pacing * Premature ventricular complex * Ventricular tachycardia * Ventricular fibrillation * Focal atrial tachycardia * Premature atrial complex * Atrioventricular reentrant tachycardia 2. Patient has undergone 'successful' routine, standard of care diagnostic electrophysiology (EP) study using intracardiac catheters as clinically indicated, guided by fluoroscopy and routine electroanatomic mapping, intracardiac echocardiography, and/or cardiac imaging such as CT or MRI. 3. Patient has 12 lead electrogram data of clinical rhythms recorded on electrogram recording system. 4. Patient has undergone a successful ablation procedure. 5. Arrhythmia type and atrial/ventricular characteristics can be abstracted from patient medical records. 6. Patient was between 22 and 100 years of age at time of EP study and ablation procedure.

Exclusion criteria

Patients with unstable coronary artery disease, confirmed intracardiac thrombus, active sepsis, complex congenital heart disease, dextrocardia, severe pulmonary hypertension, decompensated heart failure, a mechanical heart valve, myocardial infarction within 1 month of ablation, inability to induce arrhythmia, unacceptable ECG data quality, and/or data included in the device training dataset.

Design outcomes

Primary

MeasureTime frame
Rate of accuracy/agreement of vMap™ in correctly identifying the ventricular chamber/region of the arrhythmia for PCV and VT.Immediately post ablation procedure through approximately 6 months post ablation procedure, based on retrospective data collection eligibility criteria.

Secondary

MeasureTime frame
Rate of accuracy/agreement of vMap™ in correctly identifying the chamber/region of the arrhythmia location for all arrhythmia types.Immediately post ablation procedure through approximately 6 months post ablation procedure, based on retrospective data collection eligibility criteria.
Rate of accuracy/agreement of vMap™ in correctly identifying the segment of the arrhythmia treatment across all arrhythmia types.Immediately post ablation procedure through approximately 6 months post ablation procedure, based on retrospective data collection eligibility criteria.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 11, 2026